Skip to main content
Log in

Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure

  • Congestive Heart Failure
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Patients with heart failure generally show improvement in their clinical condition after enoximone infusion over the period of treatment; this effect cannot be ascribed only to the known hemodynamic action of this drug. Thirty-six patients (age range 44–82 years) with heart failure (NYHA class II–IV) underwent 48-hour enoximone infusion to study whether this prolonged improvement might depend on changes in systemic or renal hemodynamics or in neurohormonal balance. All patients underwent Swan-Ganz hemodynamic monitoring; renal plasma flow, glomerular filtration rate, plasma atrial natriuretic factor (ANF), and plasma renin activity (PRA) were all measured at baseline, at the peak of the enoximone action, and 48 hours after drug discontinuation. The main hemodynamic parameters were significantly improved during enoximone infusion and after drug discontinuation. The cardiac index basal value of 2.2±0.1 l/min/m2 increased to 3.1±0.1 l/min/m2 after 24-hour therapy (p<0.01); similarly, pulmonary wedge pressure, mean pulmonary arterial pressure, and right atrial pressure decreased markedly (p<0.01). Beneficial effects were also observed in renal hemodynamics; indeed, renal plasma flow (basal value 485±39 ml/min) increased significantly after 24-hour enoximone infusion (575±35 ml/min; p<0.01), and this tendecy was also observed 48 hours after drug discontinuation. No significant modifications were observed in plasma hormone data; however, the PRA plasma level had a tendency to decrease. We conclude that in patients with heart failure, enoximone infusion has a less marked effect on renal hemodynamics, but this is more lasting than systemic hemodynamic effects. The tendency of PRA to decrease (although not statistically significant), still detectable 2 days after treatment in the presence of steady high plasma ANF concentrations, may also contribute to the paradoxical longlasting benefit despite the short-lived improvement in systemic hemodynamles after brief cycles of enoximone infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Raine AEG. Renal abnormality in congestive heart failure. In: Fozzard HA et al., eds. The Heart and Cardiovascular System. New York: Raven Press, 1992:1379–91.

    Google Scholar 

  2. Yuen JL, Sonnenblick EH, LeJemtel TH. Principles of inotropic therapy in heart failure. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:837–844.

    Google Scholar 

  3. Cohn JN. Principles of vasodilator therapy in congestive heart failure: Impact on mortality. In: Singh BN, Dzau Vj, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:791–796.

    Google Scholar 

  4. Cody RJ. Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure. Am J Cardiol 1989;63:31A-34A.

    Article  PubMed  CAS  Google Scholar 

  5. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 1993;22(Suppl A):119A-26A.

    Article  PubMed  CAS  Google Scholar 

  6. Fischer TA, Erbel R, Treese N. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 1992;44:928–945.

    Article  PubMed  CAS  Google Scholar 

  7. Blaufox MD, Merrill JP. Simplified Hippuran clearance: Measurement of renal function in man with simplified Hippuran clearance. Nephron 1955;3:274–281.

    Article  Google Scholar 

  8. Fine EJ, Axelrod M, Gorkin H, Saleemi K, Blaufoux MD. Measurement of effective renal plasma flow: A comparison of methods. J Nucl Med 1987;28:1939–1400.

    Google Scholar 

  9. Laragh JH, Brenner BM. Hypertension Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1990.

    Google Scholar 

  10. Glantz AS. Primer on Biostatistics. New York: McGraw-Hill, 1992.

    Google Scholar 

  11. Gardner MJ, Altman DG. Statistics with Confidence-Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1989.

    Google Scholar 

  12. Goldberg LI. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972; 24:1–29.

    PubMed  CAS  Google Scholar 

  13. Lokhandwala MF, Barrett RJ. Cardiovascular dopamine receptors: Physiological, pharmaceutical and therapeutic implications. J Auton Pharmacol 1982;3:189–215.

    Article  Google Scholar 

  14. Goldberg LI, Hsieh YY, Resnekov L. Newer catecholamines for treatment of heart failure and shock: An update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 1977;4:327–340.

    Article  Google Scholar 

  15. Robie NW, Goldberg LI: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine. Am Heart J 1975;90:340–347.

    Article  PubMed  CAS  Google Scholar 

  16. Van der Leyen H. Phosphodiesterase inhibition by new cardiotonic agents: Mechanism of action and possible clinical relevance in the therapy of congestive heart failure. Klin Wochenschr 1989;67:605.

    Article  PubMed  Google Scholar 

  17. Cody RJ, Kubo SH, Covit AB et al. Regional blood flow and neurohumoral responses to milrinone in congestive heart failure. Clin Pharmacol Ther 1986;39:128.

    PubMed  CAS  Google Scholar 

  18. Dazau VJ, Pratt RE. Cardiovascular pharmacology of angiotensin-converting enzyme inhibitors. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:237–247.

    Google Scholar 

  19. Iervasi G, Clerico A, Pilo A et al. Kinetic study of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy. Evidence for resistance to the biological effects of the hormone even in patients with mild myocardial involvement. J Cardiovasc Pharmacol 1994;24:626–637.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berti, S., Palmieri, C., Ravani, M. et al. Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure. Cardiovasc Drug Ther 10, 81–87 (1996). https://doi.org/10.1007/BF00051134

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051134

Key Words

Navigation